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Abstract
A proliferative response of smooth muscle cells to activation of extracellular signal regulated kinases 1 and 2 (ERK1/2) has
been linked to cardiovascular disease. In fully differentiated smooth muscle, however, ERK1/2 activation can also regulate
contraction. Here, we use A7r5 smooth muscle cells, stimulated with 12-deoxyphorbol 13-isobutylate 20-acetate (DPBA) to
induce cytoskeletal remodeling or fetal calf serum (FCS) to induce proliferation, to identify factors that determine the
outcomes of ERK1/2 activation in smooth muscle. Knock down experiments, immunoprecipitation and proximity ligation
assays show that the ERK1/2 scaffold caveolin-1 mediates ERK1/2 activation in response to DPBA, but not FCS, and that
ERK1/2 is released from caveolin-1 upon DPBA, but not FCS, stimulation. Conversely, ERK1/2 associated with the actin
cytoskeleton is significantly reduced after FCS, but not DPBA stimulation, as determined by Triton X fractionation.
Furthermore, cytochalasin treatment inhibits DPBA, but not FCS-induced ERK1/2 phosphorylation, indicating that the actin
cytoskeleton is not only a target but also is required for ERK1/2 activation. Our results show that (1) at least two ERK1/2
fractions are regulated separately by specific stimuli, and that (2) the association of ERK1/2 with the actin cytoskeleton
regulates the outcome of ERK1/2 signaling.
Citation: Vetterkind S, Saphirstein RJ, Morgan KG (2012) Stimulus-Specific Activation and Actin Dependency of Distinct, Spatially Separated ERK1/2 Fractions in
A7r5 Smooth Muscle Cells. PLoS ONE 7(2): e30409. doi:10.1371/journal.pone.0030409
Editor: Adrian John Harwood, Cardiff University, United Kingdom
Received August 26, 2011; Accepted December 15, 2011; Published February 21, 2012
Copyright:  2012 Vetterkind et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health (www.nih.gov) grant numbers HL80003 and HL86655. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: svetter@bu.edu
Introduction
Activation of extracellular signal regulated kinases 1 and 2
(ERK1/2) leads to a proliferative response in many cell types,
including smooth muscle, where it has been connected with
pathologic hypertrophy and hyperplasia, prerequisites for the
development of hypertension and atherosclerosis [1,2,3,4]. Fur-
thermore, elevated ERK1/2 activity has been shown in athero-
sclerotic lesions of cholesterol-fed rabbits [5]. On the other hand, it
has been demonstrated that ERK1/2 activation can regulate
contractility in fully differentiated smooth muscle [6,7,8], and
ERK1/2 has been shown to contribute to elevated tone in
hypertensive rats [9].
ERK1/2 is activated by threonine and tyrosine phosphorylation
by the dual specificity kinase MEK, which, in turn, is activated by
Raf. Components of the MAPK cascade can be assembled by a
variety of scaffold proteins, and these have been shown to regulate
ERK1/2 cytoplasmic retention versus nuclear translocation (for
review, see [10,11]). However, subcellular targeting of ERK1/2 by
scaffold proteins cannot fully explain the different outcomes of
ERK1/2 activation, since even cytoskeletal ERK1/2 scaffolds have
been associated with proliferative ERK1/2 signaling [12,13]. Thus,
it is still not clear how ERK1/2 activation can be directed towards
proliferation in some settings, and towards contraction in others.
That ERK1/2 activity can be regulated by caveolin-1 is widely
agreed upon, however, both activation and inhibition of ERK1/2
by caveolin-1 have been reported [14,15,16,17,18,19]. Caveolin-1
is the characteristic membrane protein in flask-like membrane
invaginations, caveolae. It is expressed at high levels in contractile
smooth muscle, and high expression levels correlate with and,
moreover, support the contractile phenotypic state of smooth
muscle cells [20]. Therefore, caveolin-1 is a good candidate for
mediating contractile, as opposed to proliferative, ERK1/2
stimulation in smooth muscle.
In the present study we use, as a model system, the smooth
muscle derived A7r5 cell line to investigate what factors determine
the outcome of ERK1/2 signaling in smooth muscle cells. A7r5
cells re-acquire a smooth muscle-like phenotype, as determined by
the upregulation of smooth muscle marker proteins such as alpha
actin, basic calponin and SM22 after growth to confluency and
serum starvation [21,22,23]. ERK1/2 activation was induced
either by the phorbol ester, 12-deoxyphorbol 13-isobutylate 20-
acetate (DPBA), or by fetal calf serum (FCS) stimulation. These
two stimuli, although both induce ERK1/2 activation, produce
very different effects: DPBA triggers ERK1/2 dependent cyto-
skeletal remodeling and formation of podosomes [24,25], whereas
FCS induces proliferation [26]. Using this model system we report
here that different pools of ERK1/2 exist in the same cell type and
that they are differentially affected by specific stimuli. Phorbol
esters release activated ERK1/2 from caveolae in an actin
dependent manner, and simultaneously activate cytoskeletal
ERK1/2, whereas a proliferative stimulus does not affect caveolar
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outcomes.
Results
Caldesmon phosphorylation in response to a phorbol
ester depends on ERK1/2
ERK1/2 is phosphorylated after both DPBA and FCS
stimulation of A7r5 smooth muscle cells (Figure 1A). Phosphor-
ylation of the actin-binding ERK1/2 substrate caldesmon has
been shown to mediate podosome formation in response to
phorbol ester stimulation of protein kinase C through activation of
ERK1/2 [25]. Therefore, to test whether caldesmon mediates the
different effects of DPBA versus FCS stimulation, we analyzed
caldesmon phosphorylation in response to these two stimuli.
Interestingly, our results show that caldesmon, like ERK1/2, is
phosphorylated in response to both DPBA and FCS stimulation.
However, DPBA induced phosphorylation of caldesmon fully
depends on ERK1/2 activation, since in the presence of the MEK
inhibitor U0126, caldesmon phosphorylation is reduced to
background levels. In contrast, after FCS stimulation, caldesmon
phosphorylation is reduced by roughly 30% in the presence of
U0126, indicating that caldesmon phosphorylation is only partly
mediated by ERK1/2 after FCS stimulation (Figure 1B). Yet,
although in both types of stimulation ERK1/2 and caldesmon are
phosphorylated, DPBA stimulation leads to podosome formation,
while FCS stimulation does not (Figure 1C). These observations
prompted us to test whether specific ERK1/2 subfractions are
activated in a stimulus specific manner.
Caveolin-1 mediates ERK1/2 activation in response to
phorbol ester, but not serum stimulation
Caveolin-1 has been shown to act as an ERK1/2 scaffold in
smooth muscle, and interference with caveolin-1 signaling in a
decoy peptide approach reduced the contraction of smooth muscle
tissue after PKC-mediated contractile stimulation [16]. With the
help of siRNA experiments to knock down endogenous caveolin-1
expression, we have tested the hypothesis that caveolar ERK1/2 is
affected differently by stimuli that lead to cytoskeletal remodeling
(DPBA) or proliferation (FCS). Control experiments demonstrate
that caveolin-1 siRNA reduces the expression of caveolin-1 by
approximately 65%, whereas control siRNA against caveolin-2
Figure 1. ERK1/2 activation has stimulus-specific effects on the A7r5 cytoskeleton. (A) ERK1/2 is phosphorylated in response to both,
DPBA and FCS. A7r5 cells stimulated with either DPBA or FCS for the indicated time points were processed for western blot analysis of total ERK1/2
and phospo-ERK1/2. After densitometry analysis, no significant differences in ERK1/2 phosphorylation (normalized to total ERK1/2) were detected. (B)
A7r5 cells were pre-treated with the MEK inhibitor U0126 for 60 minutes, then stimulated with DPBA or FCS, or left untreated, for additional
60 minutes before preparation of cell lysates. Lysates were analyzed by western blotting and densitometry. Please note that in the presence of the
MEK inhibitor, caldesmon phosphorylation in response to DPBA is completely blocked, whereas caldesmon phosphorylation (normalized to tubulin)
in response to FCS is reduced by only about 30%. Statistical significance was tested by a two-tailed Student’s T-Test (**p,0.01 U0126 vs. control,
##p,0.01 DPBA vs. FCS). (C) A7r5 cells grown on coverslips were treated as indicated for 60 minutes, then fixed and stained for fluorescence
microscopy with phalloidin to visualize actin filaments. Please note the cytoskeletal rearrangements and the appearance of podosomes in the DPBA
treated cells (arrows). Scale bar, 20 mm.
doi:10.1371/journal.pone.0030409.g001
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affect caveolin-1 expression (Figure 2A). Western blot followed by
densitometry analysis revealed that after siRNA knock down of
caveolin-1, ERK1/2 phosphorylation (normalized to total ERK1/
2) in response to DPBA, but not FCS, is significantly reduced by
approximately 30% (Figure 2B). In the caveolin-1 siRNA treated
cells, but not the control cells, ERK1/2 phosphorylation in
response to DPBA is also significantly reduced when DPBA and
FCS stimulated groups were compared. These findings indicate
that caveolin-1 promotes ERK1/2 activation in a stimulus-specific
manner. Separate analysis of ERK1 and ERK2 shows that the
effect of caveolin-1 siRNA was more pronounced for ERK2 than
for ERK1. Significance was reached for the DPBA stimulated
CaV-1 siRNA samples compared to FCS stimulated CaV-1
siRNA samples (p,0.014) as well as compared to DPBA
stimulated control samples (p,0.015). ERK1 is also reduced in
the CaV-1 knock down samples, but the difference is not quite
statistically significant.
A caveolar ERK1/2 fraction is phosphorylated and
released after phorbol ester stimulation
To investigate how the interaction of caveolin-1 and ERK1/2 is
affected by DPBA versus FCS stimulation, we first utilized
proximity ligation assays (Olink, Uppsala, Sweden) with anti-
caveolin-1 and anti-ERK1/2 specific antibodies (Figure 3A). Data
obtained from these experiments show that proximity of caveolin-
1 with phospho-ERK1/2 is markedly enhanced after 10 minutes
of DPBA stimulation and slightly enhanced after 10 minutes FCS
stimulation. At the same time point, proximity of caveolin-1 and
total ERK1/2 is significantly reduced after DPBA stimulation, but
not affected by FCS stimulation. These results suggest that a
caveolar fraction of ERK1/2 is released from caveolae upon
ERK1/2 phosphorylation after DPBA, but not after FCS
stimulation. To investigate the time course of ERK1/2 and
caveolin-1 interaction in more detail, we performed IP experi-
ments with an anti-caveolin-1 antibody. Time points analyzed
were 0 minutes, 1 minute, 5 minutes, 10 minutes, 30 minutes and
60 minutes, but for clarity, data are grouped into unstimulated
(0 minutes), early (1–10 minutes) and late (30–60 minutes), with
the early timepoints comprising the observed peak of ERK1/2
phosphorylation (Figure 1A) between 5 and 10 minutes. Co-
immunoprecipitates were analyzed for phospho-ERK1/2
(Figure 3B) and total ERK1/2 (Figure 3C), both normalized to
immunoprecipitated caveolin-1. Phospho-ERK1/2 was found to
co-precipitate at early time points after DPBA stimulation with the
strongest co-precipitation detected between 5 and 10 minutes, but
not at later time points. For total ERK1/2, a small non-significant
increase of binding to caveolin-1 was observed early after DPBA
Figure 2. Knock down of caveolin-1 interferes with DPBA induced ERK1/2 phosphorylation. A7r5 cells were transfected with caveolin-1
siRNA, caveolin-2 siRNA as control or left untransfected. Experiments were performed five days after transfection. (A) Western blot analysis and
statistical analysis of densitometry analysis show efficient knock down of caveolin-1. Statistical significance was tested by two-tailed Student’s T-Tests
(***p,0.001 siRNA vs. control,
###p,0.001 siRNA vs. untransfected). (B) Five days after siRNA transfection, cells were stimulated with either DPBA or FCS, or
left untreated. Lysates were analyzed for ERK1/2 phosphorylation by western blotting and densitometry. The graph shows that after caveolin-1 knock down,
the rate of ERK1/2 phosphorylation is significantly reduced in response to DPBA, but not FCS. Statistical significance was tested by two-tailed Student’s
T-Tests (**p,0.01 siRNA vs. control,
##p,0.01 DPBA vs. FCS).
doi:10.1371/journal.pone.0030409.g002
Actin Dependency of ERK1/2 Pools
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e30409stimulation, however, at later time points the association of
ERK1/2 and caveolin-1 was significantly reduced, compared to
both, unstimulated and FCS stimulated. In contrast, no significant
change in binding of phosphorylated or total ERK1/2 was found
after FCS stimulation. The results confirm that the fraction of
ERK1/2 that is associated with caveolin-1 under unstimulated
conditions can be phosphorylated and subsequently released in a
stimulus-specific manner.
Filamentous localization of phospho-ERK1/2 is lost after
caveolin-1 knock down
The data from the knock down and IP experiments suggest that
the reduction in ERK1/2 phosphorylation after caveolin-1 knock
down represents the caveolar ERK1/2 fraction only. We therefore
applied immunofluorescence analysis of phospho-ERK1/2 to
show whether the effect of caveolin-1 knock down on ERK1/2
phosphorylation is localization dependent (Figure 4). Surprisingly,
imaging with a phospho-specific ERK1/2 antibody revealed that
phospho-ERK1/2 shows stimulus-specific staining patterns, with
DPBA causing a filamentous staining pattern (B) and FCS
resulting in diffuse, mainly perinuclear staining (J). Furthermore,
after caveolin-1 siRNA treatment, the ERK1/2 phosphorylation
in response to DPBA was reduced and filamentous staining was
lost (F). FCS-induced ERK1/2 phosphorylation was not affected
(N), as expected from the results presented in Figure 1B. Co-
staining of DPBA treated cells with phospho-ERK1/2 and either
alpha smooth muscle actin or phalloidin to visualize actin
filaments confirmed that filamentous ERK1/2 staining colocalizes
with actin stress fibers (Supporting Information S1).
Insoluble ERK1/2 fractions are activated and mobilized in
a stimulus-specific manner
Since in the immunofluorescence experiments, a caveolar
fraction of ERK1/2 is not clearly identifiable due to resolution
limitations, we used a Triton X-100 (TX) extraction/western blot
approach to analyze what fraction of ERK1/2 is associated with
caveolae and how it is affected by stimulation. The caveolar
fraction is insoluble at 4uC, but not at 37uC, whereas the
cytoskeletal fraction is insoluble at both conditions. Experiments
were carried out in parallel at 4uC and at 37uC to allow for
calculation of the caveolar fraction and the non-caveolar,
presumably mainly cytoskeletal fraction. Surprisingly, as shown
in Figure 5A, almost 50% of total ERK1/2 was found in the
insoluble fraction of unstimulated cells, most of it non-caveolar. In
response to serum stimulation, ERK1/2 showed increased
solubility and was significantly reduced in the insoluble fraction,
while the amount of ERK1/2 in the caveolar fraction was
unchanged, indicating that ERK1/2 is recruited from the
cytoskeleton, but not from caveolae, for nuclear translocation
after serum stimulation. DPBA stimulation reduced the amount of
caveolar ERK1/2 by 50%, as expected from the experiments
shown in Figure 3, but had little effect on the non-caveolar
insoluble ERK1/2 fraction, suggesting that the cytoskeletal
fraction of ERK1/2 remains bound to the cytoskeleton and is
not released in response to DPBA. The results shown in Figure 5A
represent data from late time points of stimulation (30 and
60 minutes), however, analysis of early time points (1–10 minutes)
also revealed a significant reduction of the non-caveolar insoluble
Figure 3. A caveolar fraction of ERK1/2 is phosphorylated and
mobilized in a stimulus-specific manner. (A) A7r5 cells grown on
coverslips were stimulated with DPBA or FCS, or left unstimulated, and
then fixed and stained with a caveolin-1 antibody and either an ERK1/2
or phospho-ERK1/2 antibody. Cells were processed for proximity
ligation assays (Olink) according to the manufacturer’s protocol and
then analyzed for signal dots indicative of close proximity. (B and C)
A7r5 cells were treated with either DPBA or FCS for the indicated times.
Lysates were then subjected to immunoprecipitation with an anti-
caveolin-1 antibody. Immunoprecipitates were analyzed for co-immu-
noprecipitation of (B) phospho-ERK1/2 and (C) total ERK1/2 by western
blotting and densitometry. Please note that interaction of caveolin-1
with phospho-ERK1/2 is increased at early time points after DPBA, but
not FCS stimulation, whereas interaction with total ERK1/2 is reduced at
later time points of DPBA, but not FCS stimulation. Statistical
significance was tested by two-tailed Student’s T-Tests (*p,0.05,
***p,0.001 DPBA vs. unstimulated;
#p,0.05,
##p,0.01,
###p,0.001
,0.001 DPBA vs. FCS;
+p,0.05 FCS vs. unstimulated).
doi:10.1371/journal.pone.0030409.g003
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DPBA stimulated), and a significant smaller caveolar fraction after
DPBA stimulation compared to FCS stimulation. These results are
corroborated by immunofluorescence imaging of phospho-ERK1/
2 in DPBA or FCS stimulated (60 minutes) or unstimulated cells
with and without TX-extraction at 37uC before fixing. As shown
in Figure 5B, the filamentous phospho-ERK1/2 staining observed
after DPBA stimulation is resistant to TX extraction. In contrast,
the nuclear and diffuse perinuclear phospho-ERK1/2 staining
that is seen after FCS stimulation is lost after TX-extraction.
The actin cytoskeleton is required for ERK1/2 activation
in response to a phorbol ester
To further evaluate the role of the actin cytoskeleton in
channeling of ERK1/2 signaling, we analyzed ERK1/2 phos-
phorylation after disruption of the actin cytoskeleton (Figure 5C).
To this end, cells were pretreated with the inhibitor of actin
polymerization, cytochalasin D before stimulation with serum or
DPBA for 60 minutes. The results show that cytochalasin D
reduces ERK1/2 phosphorylation in response to DPBA by
approximately 40%, but has no significant effect on serum-
mediated ERK1/2 phosphorylation, demonstrating that an intact
actin cytoskeleton is essential for activation of ERK1/2 after
DPBA stimulation.
Discussion
The main finding of the present study is that in smooth muscle
cells, physically distinct ERK1/2 subfractions are stimulated
separately by specific stimuli. Based on our data, we suggest that
at least two insoluble ERK1/2 fractions exist (see model in
Figure 6), namely a caveolar and a cytoskeletal ERK1/2 fraction,
and that phorbol ester stimulation mobilizes the caveolar pool and
activates the cytoskeletal pool, whereas serum stimulation leads to
a release of cytoskeletal ERK1/2 into the soluble ERK1/2 pool.
The precise role of caveolin-1 and caveolae as scaffolds for
MAPK signaling is still under debate. Many groups have reported
enhanced ERK1/2 activation after cholesterol depletion to
remove caveolae, or after knock down of caveolin-1, indicating
an inhibitory role for caveolae in MAPK signaling [14,15,17]. In
smooth muscle, caveolin-1 can direct growth factor signaling to
either a proliferative or an apoptotic response [18]. Furthermore,
caveolin-1 has been shown to regulate smooth muscle contractility
[16,19]. Our findings suggest that in smooth muscle, caveolae can
both, sequester ERK1/2 molecules to withdraw them from the
soluble pool, and facilitate ERK1/2 signaling, depending on the
stimulus. This points to a trendsetting function of caveolae in
inhibiting proliferative ERK1/2 signaling, while at the same time
facilitating cytoskeletal ERK1/2 signaling, which is in line with the
positive correlation between differentiation status and expression
level of caveolin-1 in smooth muscle [20] and also explains the
apparently contradictory roles that caveolae seem to play in
MAPK signaling.
The caveolar ERK1/2 fraction, that was activated and
mobilized in response to DPBA, represented a relatively small
percentage of total ERK1/2 of about 10%, which was surprising
in light of the well known function of caveolin-1 as an ERK1/2
regulator. This number is feasible, though, given that catalytic
Figure 4. Stimulus-specific cytoskeletal localization of phospho-ERK1/2 depends on caveolin-1. A7r5 cells grown on coverslips were
transfected with caveolin-1 siRNA and control siRNA. Five days after transfection, cells were stimulated with either DPBA or FCS for 60 minutes, or left
untreated. After stimulation, cells were fixed and stained for caveolin-1 (a, e, I, m), phospho-ERK1/2 (b, f, j, n) and DAPI (c, g, k, o); merged images are
shown in panels d, h, l, p. Please note that in the caveolin-1 knock down cells, the filamentous phospho-ERK1/2 staining seen after DPBA stimulation
is absent in caveolin-1 knock down cells (arrows). Scale bar, 20 mm.
doi:10.1371/journal.pone.0030409.g004
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downstream effects because of signal amplification. However, it
might also be an underestimation of the real ERK1/2 percentage
in the caveolar fraction, since in density gradient fractionations,
roughly 20% of total ERK1/2 was found in the caveolar fraction
(Supporting Information S1), indicating that not all of the caveolar
ERK1/2 is pulled down together with caveolin-1 in IP
experiments. Due to the small size of the caveolar ERK1/2
fraction, we were not able to resolve where activated caveolar
ERK1/2 is targeted after mobilization. However, the observed
dependence of activation of cytoskeletal ERK1/2 on caveolin-1
(Figure 4) and thus, on functional caveolae, suggests a link between
the caveolar and cytoskeletal ERK1/2 fractions. Therefore, it
seems likely that activated caveolar ERK1/2 is targeted to the
cytoskeleton.
An unexpectedly large percentage of total ERK1/2 was found
in a Triton X insoluble cytoskeletal compartment in unstimulated
cells, and after DPBA stimulation, phospho-ERK staining
displayed a filamentous pattern indicative of cytoskeletal associa-
tion. Although ERK1/2 has several cytoskeletal interaction
partners and substrates [27,28,29,30], there are few reports about
cytoskeletal association of ERK1/2, most of them showing
ERK1/2 in a Triton X-insoluble fraction in protein biochemistry
experiments [31,32,33,34]. Of note, ERK1/2 has been shown to
bind to actin directly in vitro [32]. Imaging of phospho-ERK1/2
associated with the actin cytoskeleton has, to the best of our
knowledge, only been shown for NIH3T3 cells [35] and vascular
smooth muscle cells [36,37], but the functional significance of
actin association of ERK1/2 has, so far, not been investigated in
detail. We show here that in smooth muscle cells (1) a large
fraction of total ERK1/2 is associated with the actin cytoskeleton
in a Triton X-insoluble manner, (2) is targeted differently by
different stimuli, (3) can be activated in a caveolin-1 dependent
manner, and (4) provides an important actin-dependent fraction of
activated ERK1/2 after phorbol ester stimulation, thus clearly
linking ERK1/2 function to the actin cytoskeleton.
Immobilization of ERK1/2 in a cytoskeletal pool could account
for some of the differences in ERK1/2 signaling that have been
observed in smooth muscle cells [6,7,8] versus other cell and tissue
types [38,39,40], and also for the different directions of ERK1/2
signaling (contraction versus proliferation) in fully differentiated,
contractile smooth muscle versus synthetic, non-contractile smooth
muscle [41,42]. It is tempting to speculate that, since contractile
smooth muscle contains high levels of actin and other cytoskeletal
proteins, the protein equipment of contractile cells could directly
channel ERK1/2 activation towards cytoskeletal targets and thus,
Figure 5. The cytoskeletal fraction of ERK1/2 is mobilized upon FCS, but not DPBA, stimulation. (A) A7r5 cells were treated with either
DPBA or FCS and then subjected to subcellular fractionation into cytoskeletal and soluble fractions by Triton X-100 extraction. ERK1/2 subcellular
distribution was analyzed by western blotting and densitometry. The graph shows the percentage of total ERK1/2 found in the caveolar and non-
caveolar (cytoskeletal) TX-insoluble fractions at late time points of stimulation (30 minutes and 60 minutes). Statistical significance was tested by two-
tailed Student’s T-Tests (non-caveolar insoluble fraction: *p,0.05 DPBA vs. FCS, **p,0.01 unstimulated vs. FCS; caveolar insoluble fraction:
#p,0.05
DPBA vs. FCS). (B) A7r5 cells were grown on coverslips were subjected to TX extraction before fixing and staining for phospho-ERK1/2. Please note
that filamentous phospho-ERK1/2 staining after DPBA stimulation is TX resistant, while the nuclear and diffuse perinuclear phospho-ERK1/2 staining
after FCS stimulation is not. Scale bar, 20 mm. (C) A7r5 cells, pretreated with Cytochalasin D for one hour or control treated (solvent only), were
stimulated with either FCS or DPBA, or left unstimulated, for another hour. Lysates were subjected to western blotting with a total ERK1/2 antibody
and a phospho-ERK1/2 antibody. The graph shows phospho-ERK1/2 relative to total ERK1/2. Statistical significance was tested by a paired two-tailed
Student’s T-Test (**p,0.01 Cyto D vs. control, #p,0.05 DPBA vs. FCS, n.s.=not significant).
doi:10.1371/journal.pone.0030409.g005
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presented here, ERK1/2 subcellular localization does not reflect
dynamic changes of the actin cytoskeleton: although DPBA
stimulation leads to reorganization of actin filaments in favor of
podosome formation, the cytoskeletal ERK1/2 fraction remains
associated with the actin cytoskeleton. Conversely, after FCS
stimulation, stress fibers remain intact (Figure 1A), yet ERK1/2
dissociates from the cytoskeletal fraction upon FCS stimulation.
These findings suggest that cytoskeletal association of ERK1/2 is
most likely regulated by other, stimulation-dependent factors,
rather than protein levels of actin or actin binding proteins.
In summary, we show here for the first time that in smooth
muscle, the outcome of ERK1/2 activation depends on the type of
stimulation and is determined by cytoskeletal binding of ERK1/2:
in response to serum, which mimics exposure to serum growth
factors after blood vessel injury, initially insoluble ERK1/2 is
mobilized, enabling nuclear signaling. In contrast, signaling
downstream of phorbol ester stimulation, which mimics vasocon-
strictor-induced activation of protein kinase C [43], depends on
insoluble caveolar and cytoskeletal ERK1/2 pools, resulting in
cytoskeletal remodeling. Thus, our results identify cytoskeletal
association of ERK1/2 a mechanism by which ERK1/2 signaling
can be directed either toward proliferation, as associated with
atherosclerosis [1], or toward contractility, as associated with
hypertension [9].
Materials and Methods
Reagents and antibodies
General laboratory reagents were of analytical grade or better
and were purchased from Sigma (St. Louis, MO) and Bio-Rad
(Hercules, CA). For stimulation, fetal calf serum (FCS, Invitrogen,
Carlsbad, CA) was used at 10% and 12-deoxyphorbol 13-
isobutylate 20-acetate (DPBA, LC Laboratories, Woburn, MA)
was used at 3 mM. The MEK inhibitor U0126 (Calbiochem,
Gibbstown, NJ) was used at 20 mM. Cytochalasin D (CytoD,
Cytoskeleton, Denver, CO) was used at 5 mM, as determined in
test experiments as optimal concentration for effective disruption
of the cytoskeleton. The following primary antibodies were used:
rabbit polyclonal anti-caveolin-1 (Cell Signaling, Danvers, MA),
mouse monoclonal anti-ERK1/2 (Cell Signaling), mouse mono-
clonal anti-phospho-ERK1/2 (Cell Signaling), rabbit polyclonal
anti-phospho-ERK1/2 (Cell Signaling), mouse monoclonal anti-
tubulin alpha (Sigma), rabbit polyclonal anti-phospho-caldesmon
(Millipore, Billerica, MA), rabbit polyclonal total caldesmon
(Abgent, San Diego, CA). For immunofluorescence experiments,
goat anti-rabbit and goat anti-mouse Alexa FluorH 488 and Alexa
FluorH 568 (1:1000, Invitrogen) were used as secondary antibod-
ies. Goat Oregon GreenH 488 or Alexa FluorH 568 labeled anti-
rabbit or anti-mouse IgGs were used as secondary antibodies in
western blot experiments (1:1000, LI-COR, Lincoln, NE). Nuclei
were stained with 4,6-diamidino-2-phenylindole (DAPI, Sigma),
and filamentous actin was stained with Alexa Fluor 568 phalloidin
(1:3000, Invitrogen).
Cell culture
A7r5 rat aorta cells (ATCC, Manassas, VA) were cultured in
DMEM high glucose (Invitrogen) with 10% FCS, 1% glutamine,
50 units/ml penicillin and 50 mg/ml streptomycin. To ensure
differentiation of the cells to the smooth muscle-like phenotype,
cells were grown to confluency and incubated in medium
containing 0% serum for 24 h prior to all experiments.
Immunofluorescence imaging and proximity ligation
assays
Cells were fixed and stained as previously described [44]. Nuclei
were stained with 4,6-diamidino-2-phenylindole (DAPI, Sigma),
filamentous actin was stained with Alexa FluorH 568 and Alexa
FluorH 488 phalloidin (1:3000, Invitrogen). Cells were examined
with an Eclipse TE2000-E fluorescence microscope (Nikon,
Melville, NY) equipped with a CCD camera and using filters
optimized for double-label experiments. For Triton X-100
extraction, cells were incubated in PIPES/EGTA/MgCl2 (PEM)
buffer (80 mM PIPES, pH 6.8, 1 mM EGTA, 1 mM MgCl2,4 %
PEG) containing 0.25% Triton X-100 with gentle agitation at
37uC before fixing. For proximity ligation assays (PLA) using the
Duolink in situ PLA kit (Olink, Uppsala, Sweden), coverslips were
stained with the primary antibodies, washed, and further
processed essentially according to the manufacturer’s instructions.
In brief, the coverslips were incubated with the secondary
oligonucleotide-linked antibodies provided in the kit. The
oligonucleotides bound to the antibodies were hybridized, ligated,
amplified, and detected using a fluorescent probe. Dots were
detected and counted using NIS Elements AR 2.30 software
(Nikon). Images were processed with Photoshop CS3 software
(Adobe Systems, Mountain View, CA).
Cell extracts
Prior to preparation of cell lysates, cells were either stimulated
with DPBA (3 mM) or with FCS (10%) for the indicated times, or
left unstimulated. For cytochalasin D (CytoD) or MEK inhibitor
U0126 experiments, cells were pretreated for 60 minutes, and
then stimulated or left unstimulated for another 60 minutes. To
prepare whole cell extracts, plates were washed with ice-cold PBS
and then scraped off in lysis buffer (50 mmol/L NaCl, 3 mmol/L
Figure 6. Model: Spatially distinct ERK1/2 subfractions are
activated in a stimulus-specific manner. Upon FCS stimulation, a
cytoskeletal ERK1/2 fraction is activated and released into a soluble
ERK1/2 fraction (magenta arrow), enabling nuclear ERK1/2 signaling,
whereas the caveolar ERK1/2 fraction is not activated in response to
FCS. Phorbol ester stimulation, in contrast, leads to phosphorylation of
both, caveolar and cytoskeletal ERK1/2 fractions. Caveolar ERK1/2 is
released upon activation (green arrows), while cytoskeletal ERK1/2 is
retained at actin filaments. The double headed arrow indicates a
functional link between the caveolar and cytoskeletal ERK1/2 fractions.
doi:10.1371/journal.pone.0030409.g006
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10 mmol/L sodium phosphate buffer, pH 8.0) supplemented with
protease inhibitor cocktail (Roche, Indianapolis, IN). Cells were
lysed on ice for 30 min. Lysates were cleared by centrifugation
(16,000 rcf, 10 minutes at 4uC). For Triton X-100 soluble and
insoluble cell extracts, plates were washed once with either
precooled (4uC) or prewarmed (37uC) PEM buffer. Cells were
scraped off in prewarmed PEM buffer with 0.5% Triton X-100
and incubated at 4uCo ra t3 7 uC for 3 minutes. Cells were then
pelleted by centrifugation (400 rcf at 4uC or at room temperature)
for 2 minutes. The supernatant was collected and the pellet was
resuspended in sample buffer (=Triton X-100 insoluble fraction).
Proteins in the supernatant (=Triton-X soluble fraction) were
precipitated over night after adding 2.5 volumes of Ethanol.
Precipitated protein was pelleted by centrifugation (16,000 rcf,
10 minutes at 4uC) and resuspended in sample buffer.
Immunoprecipitation and western blot
For immunoprecipitation experiments, A7r5 lysates were pre-
cleared with empty beads and subjected to immunoprecipitation
with a rabbit polyclonal anti-caveolin-1 antibody (Cell signaling)
cross-linked to Protein G-dynabeadsH (Invitrogen) at 4uC for
3 hours. The immobilized antigen-antibody complexes were
washed three times with lysis buffer and eluted in sample buffer.
Proteins in the samples were separated on 10% SDS polyacryl-
amide gels according to standard procedures. For western blot
analysis, proteins on SDS gels were transferred onto nitrocellulose
membranes (Whatman, Florham Park, NJ). Bound proteins were
detected with specific primary antibodies and appropriate
secondary antibodies. Bands were visualized on an OdysseyH
infrared imaging system (LI-COR). Densitometry analysis was
perfomed with the Odyssey 2.1 software. Phospho-ERK1/2 was
normalized to total ERK1/2 co-stained on the same membranes,
phospho-caldesmon was normalized to total caldesmon on
duplicate membranes. Ponceau staining was used to monitor
equal protein loading and transfer.
siRNA knock down
For knock down experiments, the following siRNA oligonucle-
otides (Dharmacon, Lafayette, CO) were used: 59-CGUCGAAA-
CUGUGUGUCCCUU-39 (antisense) and 39-GGGACACACA-
GUUUCGACGUU-59 (sense) directed against caveolin-1 and 59-
UUGUAGAUCACGUAUUUGCUU-39 (antisense) and 59-
GCAAAUACGUGAUCUACAAUU-39 (sense) directed against
caveolin-2 (=control). Transfection with 40 nmol/L pre-hybrid-
ized siRNA molecules was performed with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. Cells
were processed for experiments 5 days after siRNA transfection.
Statistical analysis
All values given in the text are mean 6 SE. Differences between
means were evaluated using a two-tailed Student’s t-test.
Significant differences were taken at the p,0.05 level.
Supporting Information
Supporting Information S1 Co-localization of phospho-
ERK1/2 with filamentous actin and ERK1/2 distibution
between caveolar and non-caveolar fractions. (A) A7r5
cells were stimulated with either DPBA or FCS for 10 minutes, or
left unstimulated, and then fixed and stained for immunofluores-
cence microscopy with a phospho-ERK1/2 antibody. Cells were
co-stained with phalloidin to visualize actin filaments and with
DAPI to visualize nuclei. Please note the filamentous ERK1/2
staining after DPBA stimulation (E and H, arrowheads), and the
stronger nuclear ERK1/2 staining after FCS stimulation (I and L,
arrows) compared to DPBA stimulation (E and H, arrows). Scale
bar, 20 mM. (B) Unstimulated A7r5 lysates were subjected to
density gradient ultracentrifugation, and fractions (numbered from
top to bottom) were analyzed for total ERK1/2 in western blots.
The caveolar fractions were determined by co-staining the
membranes with a caveolin-1 antibody. The percentage of
ERK1/2 in the caveolar fraction was determined by densitometry
(n=3).
(PDF)
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